Home
overview

SMi proudly present their 5th annual COPD: Novel Therapeutics and Management Strategies conference taking place in Central London on Wednesday 16th and Thursday 17th October, 2013. Following on in this successful series, this year’s event will expand on last year’s themes to provide cutting edge concepts in COPD from the experts within industry and academia.

As the spread of the disease increases year upon year, there is increased demand for research into the diagnosis, treatment, and management of COPD. The rapidly growing market requires innovations, novel therapies, and successful management strategies to be constantly developed and optimised to combat this debilitating disease. This conference will draw upon experts from the forefront of the industry to provide delegates with solid science and up-to-date pre-clinical and clinical data within COPD that address these specific areas.

This year’s agenda will look to evolve from last year’s conference and include successful and important sessions such as, exacerbations, as well as including more in-depth information on areas, including lung biomarkers, combination therapies, comorbidities, immunology, optimising patient selection in trials, and challenges in COPD drug discovery and development. This market-leading event will be led by key opinion leaders and industry experts to provide current advances, issues, and challenges as well as an unrivalled opportunity for debate and discussion.

  • Hear the cutting edge research and development on COPD from the industry’s leading experts.
  • Examine novel diagnostic techniques and methods that can improve identifying early stages of the disease.
  • Focus on sessions involving the latest on alternative causations, exacerbations, and small airways disease.
  • Discuss advances and challenges in the development of treatment methods and strategies to improve patient treatment adherence

Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Prinicple Scientists, Associates, Project Leaders, Specialists, and Managers in the following areas:

  • Respiratory Physiology & Medicine
  • Respiratory Pharmacology
  • Medical Affairs
  • Inflammatory Disease
  • Respiratory, Inflammation and Autoimmunity
  • Pulmonary Disease
  • Respiratory Therapeutics
  • Immunology
  • Medical & Inhalation Devices
  • In-Vitro Biology
  • Biomarker
  • Inflammation Discovery
  • Preclinical R&D
  • Clinical Pharmacology
  • Clinical Trials
  • Clinical Science
  • Discovery
  • Global Data Informatics
  • Business Development
  • Brand Manager
  • Commercial
  • Respiratory Licensing & Regulation

 

 

 

AstraZeneca; Axikin; Biomedical Systems Europe; Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer-Ingelheim; Bristol Royal Infirmary; Glaxo Smith Kline; Glaxosmithkline Biologicals; GSK Biologicals; Imperial School Of Medicine London; Inamed GmbH; Kyorin Pharmaceutical Co Ltd; Laboratorios Almirall; MHRA; Mundipharma International; National Heart and Lung Institute Imperial College; Novartis; Novartis Pharma AG; Pfizer; PPD Development GmbH & Co.KG; Prosonix Ltd; Revotar Biopharmaceuticals; Sandoz International Gmbh; St Georges University of London; St George's, University of London; Teva UK Ltd; UCL Medical School; University College London; University of Cambridge School of Clinical Medicine; University of Edinburgh; University Of Oxford; Vectura; Vitalograph.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Matthew Catley

Matthew Catley, Team Leader RIA, AstraZeneca

9:10 Global outlook on COPD

Maria Belvisi

Maria Belvisi, Professor of Respiratory Pharmacology, Imperial College

Overview of current field

Update on advances
Challenges faced by the industry
Resulting impact on the future of COPD
 

9:50 Background immunology of COPD

Matthew Catley

Matthew Catley, Team Leader RIA, AstraZeneca

Overview of the immunology of COPD
Immune responses relevant to COPD
Comparing responses

10:30 Morning Coffee

11:00 Inhaled efficacious dose translation from rodent to human: A retrospective analysis of clinical standards

Jonathan Phillips

Jonathan Phillips, Principal Scientist, Amgen

Human dose projections needed to plan preclinical toxicology studies
Introduction to preclinical efficacy studies for inhaled drugs
Define and calculate the dose deposited in the lung
Extrapolation of allometric exponent needed to predict clinical dose
 

11:40 Targeting SHIP1 activation: Role in COPD and other inflammatory diseases

Stephen  Shrewsbury

Stephen Shrewsbury, Senior VP, Clinical Development and CMO, Aquinox Pharmaceuticals

SHIP1 regulates the PI3K pathway and immune cell migration and activation

SHIP1 deficiency results in chronic mucosal inflammation and fibrosis

AQX-1125 is a potent and selective allosteric activator of SHIP1

AQX-1125 has demonstrated safety and activity in human trials of airway inflammation

AQX-1125 is a once-a-day oral product in Phase II trials for COPD and Interstitial Cystitis

 

12:20 Networking Lunch

13:50 Role of the ATP-P2X7-inflammasome axis in smoke induced airway inflammation

Mark Birrell

Mark Birrell, Research Lecturer, Imperial College London

Murine smoke driven model development
Markers of ATP-P2X7-inflammasome in model system and human samples
Probing the role of each component of the axis
Investigation into the mechanism driving the ATP release
 

14:30 Effective treatment past, present, and future

Ewan Walters

Ewan Walters, Medical Director, Teva UK Ltd

Epidemiology and causes of COPD
Treatment of COPD – focus on mucolytics
Effective treatment requires effective diagnosis: review computer aided diagnostics
Cost-benefit of a structured approach
 

15:10 Insights in COPD pathobiology: Making sense of subtle clinical signals and animal models

Chris Stevenson

Chris Stevenson, Head of Translational Biology, Novartis Horsham Research Centre

Bioinformatic-based approaches that can be used to detect molecular changes that correlate with disease progression

Bioinformatic-based approaches that can be used to understand translational utility of preclinical models

Role of metabolic pathways in the response to smoke exposure

Innate immune signalling networks in COPD disease progression

 

 

15:50 Chairman’s Closing Remarks and Close of Day One

Matthew Catley

Matthew Catley, Team Leader RIA, AstraZeneca

16:00 Afternoon Tea

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

9:10 Aetiology and mechanisms of exacerbations

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

Aetiology of exacerbations: Viruses vs. bacteria
Mechanism in viral and bacterial exacerbations
Inflammatory mechanisms in exacerbations
Implications for future treatment

9:50 Assessing exacerbations in COPD clinical trials

Rosa Lamarca

Rosa Lamarca, Head of Clinical Statistics, Almirall

The course and nature of COPD exacerbations. What are we measuring?

Similarities and differences between healthcare resource utilisation definition and EXAcerbations of Chronic pulmonary disease Tool (EXACT)

How exacerbations relate with other health outcomes

 

10:30 Morning Coffee

11:00 Translational issues for exacerbations: From animals to clinics

Liz Hardaker

Liz Hardaker, Investigator III, Novartis

Critical review of animal models

Why animal models are effective
Issues and controversies surrounding models
 

11:40 p38 MAP kinase inhibitors as a novel anti-inflammatory therapy for COPD

Iain Kilty

Iain Kilty, Respiratory Disease Area Lead, Pfizer

Confidence in rationale

Oral vs inhaled delivery
Early clinical encouragement
 

12:20 Networking Lunch

13:30 Inflammation in COPD and anti-inflammatory effects of current and new treatments

Thomas Eichholtz

Thomas Eichholtz , Senior Director Drug Discovery, Almirall

Inflammation in COPD. What we know, what we don't know?
anti-inflammatory effects of current treatments
new anti-inflammatory mechanisms, chemokines, signalling pathways & other approaches
 

14:10 Pleasures and pitfalls of LABA development today

Carol Astbury

Carol Astbury, Head of Early Global Development, Almirall

LABA landscape
Development challenges in today´s environment
New LABAs: case studies and lessons learned

14:50 COPD Clinical Perspective - Food for pharma thought

Paul Ford

Paul Ford, Consultant Physician and Medical Director, Innovo Medical

15:30 Chairman’s Closing Remarks and Close of Day Two

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

15:40 Afternoon Tea

+

FEATURED SPEAKERS

Iain Kilty

Iain Kilty

Respiratory Disease Area Lead, Pfizer
Matthew Catley

Matthew Catley

Team Leader RIA, AstraZeneca
Sebastian Johnston

Sebastian Johnston

Professor of Respiratory Medicine, Imperial School Of Medicine London

Carol Astbury

Head of Early Global Development, Almirall
Carol Astbury

Chris Stevenson

Head of Translational Biology, Novartis Horsham Research Centre
Chris Stevenson

Daniel Bock

Chief Scientific Officer, Revotar Biopharmaceuticals
Daniel Bock

Ewan Walters

Medical Director, Teva UK Ltd
Ewan Walters

Iain Kilty

Respiratory Disease Area Lead, Pfizer
Iain Kilty

Jens Hohlfeld

Division Director Airway Research, Fraunhofer Institut
Jens Hohlfeld

Jonathan Phillips

Principal Scientist, Amgen
Jonathan Phillips

Liz Hardaker

Investigator III, Novartis
Liz Hardaker

Maria Belvisi

Professor of Respiratory Pharmacology, Imperial College
Maria Belvisi

Mark Birrell

Research Lecturer, Imperial College London
Mark Birrell

Matthew Catley

Team Leader RIA, AstraZeneca
Matthew Catley

Paul Ford

Consultant Physician and Medical Director, Innovo Medical
Paul Ford

Rosa Lamarca

Head of Clinical Statistics, Almirall
Rosa Lamarca

Sebastian Johnston

Professor of Respiratory Medicine, Imperial School Of Medicine London
Sebastian Johnston

Stephen Shrewsbury

Senior VP, Clinical Development and CMO, Aquinox Pharmaceuticals
Stephen  Shrewsbury

Thomas Eichholtz

Senior Director Drug Discovery, Almirall
Thomas Eichholtz

Marriott Regents Park

128 King Henry's Road
London NW3 3ST
United Kingdom

Marriott Regents Park

This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.